AFMD Key Statistics, Chart & Performance
The current stock price of AFMD is 0.1815 USD. In the past month the price decreased by -74.21%. In the past year, price decreased by -95.67%.
AFMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.48 | 392.22B | ||
| AMGN | AMGEN INC | 14.99 | 176.57B | ||
| GILD | GILEAD SCIENCES INC | 14.95 | 151.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.2 | 119.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.68 | 83.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 781.21 | 52.63B | ||
| INSM | INSMED INC | N/A | 36.89B | ||
| NTRA | NATERA INC | N/A | 32.30B | ||
| BIIB | BIOGEN INC | 11.26 | 27.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.39 | 20.90B | ||
| INCY | INCYTE CORP | 16.72 | 21.08B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 21.63B |
Related stock screener links
About AFMD
Company Profile
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 76 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Company Info
AFFIMED NV
Im Neuenheimer Feld 582
Heidelberg BADEN-WUERTTEMBERG 69120 DE
CEO: Adi Hoess
Employees: 76
Phone: 49621560030
AFFIMED NV / AFMD FAQ
What does AFMD do?
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 76 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
What is the stock price of AFFIMED NV today?
The current stock price of AFMD is 0.1815 USD. The price decreased by -34.95% in the last trading session.
Does AFMD stock pay dividends?
AFMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of AFMD stock?
AFMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for AFFIMED NV?
The Revenue of AFFIMED NV (AFMD) is expected to decline by -81.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is AFFIMED NV worth?
AFFIMED NV (AFMD) has a market capitalization of 2.76M USD. This makes AFMD a Nano Cap stock.
What is the next earnings date for AFMD stock?
AFFIMED NV (AFMD) will report earnings on 2025-06-09.
AFMD Technical Analysis
AFMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AFMD. Both the profitability and financial health of AFMD have multiple concerns.
AFMD Financial Highlights
Over the last trailing twelve months AFMD reported a non-GAAP Earnings per Share(EPS) of -5.18. The EPS increased by 42.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -175.1% | ||
| ROE | -406.92% | ||
| Debt/Equity | 0.35 |
AFMD Forecast & Estimates
10 analysts have analysed AFMD and the average price target is 12.24 USD. This implies a price increase of 6643.8% is expected in the next year compared to the current price of 0.1815.
For the next year, analysts expect an EPS growth of 40.97% and a revenue growth -81.84% for AFMD